CSL Ltd (ASX:CSL)
A$ 283.99 -2.35 (-0.82%) Market Cap: 137.51 Bil Enterprise Value: 153.48 Bil PE Ratio: 35.09 PB Ratio: 5.29 GF Score: 97/100

CSL Ltd R&D Investor Briefing Transcript

Oct 19, 2020 / 10:00PM GMT
Release Date Price: A$304.13 (+1.72%)
Mark Dehring
CSL Limited - Head of IR

Ladies and gentlemen, welcome to CSL's Annual Research and Development Briefing. Online with us today is Dr. Bill Mezzanotte, Executive Vice President, Head of Research and Development and Chief Medical Officer. He'll be joined by several of his senior team. Also joining us once again is Bill Campbell, Executive Vice President and Chief Commercial Officer. Bill will be providing us with some market insights on CSL's product portfolio.

Please be aware this presentation as well as the Q&A session is being webcast. And lastly, before we start, I draw your attention to the forward statement disclaimer within the slide deck.

I'll now pass you over to Bill Mezzanotte. Bill?

William Mezzanotte
CSL Limited - Executive VP, Head of Research & Development and Chief Medical Officer

Thank you, Mark. Hello, and welcome to all of you wherever you may be in the world. I have the privilege of hosting this event once again this year, and I hope you're all doing well and still coping with the challenges of COVID

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot